唐念中,陈少萍,石秀英,王君,郑兴

• 1:第二军医大学长海医院心血管内科

摘要(Abstract)：

目的通过比较我国经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后患者采用低剂量阿司匹林与高剂量阿司匹林对预防不良心脑血管事件的有效性和安全性,以及检测服用不同剂量阿司匹林后血浆中血栓烷素B2(thromboxane B2,TXB2)和P选择素的水平,探讨PCI后口服低剂量阿司匹林的策略是否适合我国人群,为我国PCI术后患者口服阿司匹林的合理剂量提供依据。方法于2011年5月至2012年12月,在长海医院心血管病科连续入选PCI术后患者400例,随机分为低剂量阿司匹林组(PCI术后阿司匹林100 mg/d)和高剂量阿司匹林组(PCI术后阿司匹林300 mg/d,服用3个月后改为100 mg/d),对入选患者分别在PCI术后住院期间,以及术后1个月、3个月、6个月及12个月时进行随访,主要终点是主要不良心脑血管事件。结果在入选的400例患者中失访11例,其余389例中包括低剂量阿司匹林组198例,高剂量阿司匹林组191例。随访3个月时共有7例患者发生心脑血管事件,其中低剂量阿司匹林组3例(1.5%),高剂量阿司匹林组4例(2.1%);低剂量阿司匹林组、高剂量阿司匹林组的次要出血事件发生率分别是7例(3.5%)和8例(4.2%),主要出血事件发生率均为2例(1.0%),两组间心脑血管事件以及出血事件发生率比较,差异均无统计学意义(P>0.05)。12个月时共有11例发生心脑血管事件,其中低剂量阿司匹林组6例(3.0%),高剂量阿司匹林组5例(2.6%);低剂量阿司匹林组、高剂量阿司匹林组的次要出血事件发生率分别是10例(5.1%)、11例(5.8%),主要出血事件发生率分别是3例(1.5%)和2例(1.0%),两组间心脑血管事件以及出血事件发生率比较,差异均无统计学意义(P>0.05)。阿司匹林上消化道症状(反酸、嗳气、上腹不适)在低剂量组、高剂量组的发生率分别是4例(2.0%)、12例(6.3%)(P<0.05),差异有统计学意义;比较两组间血浆中TXB2、P选择素水平,均无统计学差异,P>0.05。结论 PCI术后服用低剂量阿司匹林是有效和安全的;低剂量阿司匹林组上消化道症状的发生率低于高剂量组。

关键词(KeyWords)： 阿司匹林;经皮冠状动脉介入治疗;主要不良心脑血管事件;出血

Abstract:

Keywords:

基金项目(Foundation): 上海市科委科研计划项目(10411954900)

作者(Author): 唐念中,陈少萍,石秀英,王君,郑兴

参考文献(References)：

• [1]Ruygrok PN,Webster MW,Ardill JJ,et al.Vessel caliber and restenosis:a prospective clinical and angiographic study of NIR stent deployment in small and large coronary arteries in the same patient.Catheter Cardiovasc Interv,2003,59:165-171.
• [2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009).中华心血管病杂志,2009,37:4-25.
• [3]Joner M,Finn AV,Farb A,et al.Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk.J Am Coll Cardiol,2006,48:193-202.
• [4]Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105:1650-1655.
• [5]De Caterina R,Giannessi D,Bernini W,et al.Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction.Am J Cardiol,1985,55:589-590.
• [6]Weksler BB,Pett SB,Alonso D,et al.Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.N Engl J Med,1983,308:800-805.
• [7]Tohgi H,Konno S,Tamura K,et al.Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2and prostacyclin.Stroke,1992,23:1400-1403.
• [8]Ay C,Jungbauer LV,Sailer T,et al.High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant.Clin Chem,2007,53:1235-1243.
• [9]Blake GJ,Ridker PM.Novel clinical markers of vascular wall infl ammation.Circ Res,2001,89:763-771.
• [10]魏文斌,刘伟,张新霞,等.血小板膜及血清P选择素在急性冠脉综合征中的临床意义.岭南心血管病杂志,2009,15:363-365.
• [11]Malinin AI,Atar D,Callahan KP,et al.Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease.Eur J Pharmacol,2003,462:139-143.
• [12]Curtis JP,Schreiner G,Wang Y,et al.All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients.J Am Coll Cardiol,2009,54:903-907.
• [13]Laakso M,Lehto S.Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance.Atherosclerosis,1998,137(Suppl):S65-S73.
• [14]Kannel WB,D'Agostino RB,Wilson PW,et al.Diabetes,fi brinogen,and risk of cardiovascular disease:the Framingham experience.Am Heart J,1990,120:672-676.
• [15]Aoki J,Lansky AJ,Mehran R,et al.Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents:the Acute Catheterization and Urgent Intervention Triage Strategy trial.Circulation,2009,119:687-698.
• [16]Haffner SM,Lehto S,R?nnemaa T,et al.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med,1998,339:229-234.
• [17]Cabeza N,Li Z,Schulz C,et al.Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells.Diabetes,2004,53:2117-2121.
• [18]Geisler T,Mueller K,Aichele S,et al.Impact of infl ammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI:prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.Clin Res Cardiol,2010,99:743-752.
• [19]Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al.Platelet function profi les in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.Diabetes,2005,54:2430-2435.
• [20]Cryer B.Nonsteroidal anti-inflammatory drug injury//Sleisenger&Fordtran.Gastrointestinal and Liver Disease.7th ed.Philadelphia:Saunders,2002:408-430.
• [21]梁通流.阿司匹林导致胃溃疡的临床观察与分析.吉林医学,2012,3:1210-1211.
• [22]Joyal D,Freihage JH,Cohoon K,et al.The infl uence of low(81 mg)versus high(325 mg)doses of ASA on the incidence of sirolimuseluting stent thrombosis.J Invasive Cardiol,2007,19:291-294.
• [23]So D,Cook EF,Le May M,et al.Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention:observations from the Ottawa Heart Institute PCI Registry.J Invasive Cardiol,2009,21:121-127.
• [24]Jolly SS,Pogue J,Haladyn K,et al.Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention:insights from the PCI-CURE study.Eur Heart J,2009,30:900-907.
• [25]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomised factorial trial.Lancet,2010,376:1233-1243.
• [26]Harjai KJ,Shenoy C,Orshaw P,et al.Low-dose versus high-dose aspirin after percutaneous coronary intervention:analysis from the guthrie health off-label StenT(GHOST)registry.J Interv Cardiol,2011,24:307-314.